Home > Riviste > Minerva Surgery > Fascicoli precedenti > Articles online first > Minerva Surgery 2021 Aug 02

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

 

Minerva Surgery 2021 Aug 02

DOI: 10.23736/S2724-5691.21.08902-4

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

Validation of a prognostic model including the number of harvested lymph-nodes in the setting of non-small cell lung cancer patients undergoing curative resection: a multicentre analysis

Marco CHIAPPETTA 1, 2 , Giovanni LEUZZI 3, Isabella SPERDUTI 4, Emilio BRIA 1, 5, Felice MUCILLI 6, GiovanniBattista RATTO 7, Filippo LOCOCO 1, 2, Pierluigi FILOSSO 8, Lorenzo SPAGGIARI 9, Francesco FACCIOLO 10

1 Università Cattolica del Sacro Cuore, Rome, Italy; 2 Thoracic Surgery, Fondazione Policlinico Universitario A. Gemelli-IRCCS, Rome,
Italy; 3 Thoracic Surgery Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan,Italy; 4 Biostatistics, Regina Elena National Cancer Institute-IRCCS, Rome, Italy; 5 Medical Oncology, Fondazione Policlinico Universitario A. Gemelli - IRCCS, Rome, Italy; 6 Department of General and Thoracic Surgery, University Hospital SS. Annunziata, Chieti, Italy; 7 Division of Thoracic Surgery, IRCCS AOU San Martino IST, Genoa, Italy; 8 Department of Thoracic Surgery, San Giovanni Battista Hospital, University of Turin, Turin, Italy; 9 Thoracic Surgery Division, European Institute of Oncology, University of Milan, Milan, Italy; 10 Thoracic Surgery, Regina Elena National Cancer Institute-IRCCS, Rome, Italy


PDF


BACKGROUND: The prognostic role of the extension of lymphadenectomy in Non-small-cell lung cancer is still a debated and intriguing issue. The aim of this study is to validate a prognostic score including the number of resected lymph-nodes previously reported using a large multicentre dataset.
METHODS: From 01/2002 to 12/2012, data on 4858 NSCLC patients undergoing curative-intent surgery in six Institutions were retrospectively reviewed. To test the discriminative ability of the model, composed of a panel of high-risk,pathologic stage, nodal status, age, number of Resected Nodes and intermediate risk factors (gender, grading, histology), was determined. The Kaplan-Meier method was used to estimate Overall(OS), Cancer-Specific(CSS) and Disease-free Survival(DFS) curves, and the log rank test was adopted to evaluate the
differences between groups.
RESULTS: Pathological stages were: I in 46,5%, II in 24,1%, III in 27,8% and IV in 1,6% of cases. Overall, 5-years OS, CSS and DFS were 54,6%, 76,7% and 44,8%, respectively. Stratifying the sample of 3948 patients with complete data into Low-risk (LR, #107), Intermediate-risk (IR, #1268) and High-Risk (HR, #2573) groups, the optimal prognostic discrimination power of this score was confirmed (C-statistics: 0.71, 95%CI 69-73). Specifically in LR, IR and HR, 5-years OS was 83,5%, 66,4% and 46,2% (p<0.0001), 5y-CSS was 95,8%, 89% and 69% (p<0.0001), and 5y-DFS was 74,7%, 59.1% and 35,5% (p<0.0001), respectively
CONCLUSIONS: Our study confirms the optimal prognostic discrimination power of the previous prognostic model including the number of harvested nodes.


KEY WORDS: Lung cancer; Lymphadenectomy; Prognostic model; Thoracic surgery; Lymphnodes

inizio pagina